Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Healios Inc.
With
Genentech, Inc.
Age
21–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
In order to be eligible to participate in this study as a Support Partner, an individual must meet all of the following criteria:
1. Provide signed and dated informed consent form.
2. Willing to comply with all study procedures and be available for the duration of the study.
3. Male or female, aged 21 to 65 years.
4. Able to speak, read, and understand English.
5. Reside in the U.S.
6. Live with PwMS who is willing to participate in the study and who meets all of the eligibility criteria.
7. Has access to a telephone and computer or tablet with a stable internet connection as well as a web camera in a private setting.
8. Provide identification that meets the New Jersey Telemedicine Act of 2017.
9. Demonstrate basic ability to use a computer by completing the electronic ICF completion process, which requires use of a teleconferencing platform similar to what will be used during the intervention.
In order to be eligible to participate in this study as a Person with MS, an individual must meet all of the following criteria:
1. Provide signed and dated informed consent form.
2. Willing to comply with all study procedures and be available for the duration of the study.
3. Male or female, aged 21 to 65 years.
4. Self-report of Multiple Sclerosis including the date of the diagnosis (month and year) and the name of the diagnosing physician.
5. Able to speak, read, and understand English.
6. Reside in the U.S.
7. Cognitive difficulty as screened by the PDQ Cognitive Function (score greater than 20).
8. Live with Support Partner who meets all study eligibility criteria.
9. Has access to a telephone and computer or tablet with a stable internet connection as well as a web camera in a private setting.
10. Provide identification that meets the New Jersey Telemedicine Act of 2017.
11. Demonstrate basic ability to use a computer by completing the electronic ICF completion process, which requires use of a teleconferencing platform similar to what will be used during the intervention.
You may not be if
A Support Partner who meets any of the following criteria will be excluded from participation in this study:
1. Professional healthcare worker (e.g., physician, psychologist, social worker, case manager, nurse, home healthcare aide).
2. Dementia, including Alzheimer's and Lewy Bodies Dementia, as screened by CORE Therapy Assessment Form v.2.
3. Reports that PwMS partner is diagnosed with dementia, including Alzheimer's and Lewy Bodies Dementia.
4. Self-report of any change in medication treating bipolar disorder and any psychiatric condition, including a change in dosage, in the previous 6 months and as screened by CORE Therapy Assessment Form v.2.
5. Current suicidal intent as screened by CORE-OM and CORE Therapy Assessment Form v.2.
6. Currently participating in couple or family therapy.
7. An intellectual or developmental disability as screened by CORE Therapy Assessment Form v.2.
8. Evidence of significant brain injury or medical condition leading to cognitive impairment (e.g. accident, tumor) as screened by CORE Therapy Assessment Form v.2.
9. Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
A PwMS who meets any of the following criteria will be excluded from participation in this study:
1. Dementia, including Alzheimer's and Lewy Bodies Dementia, as screened by CORE Therapy Assessment Form v.2.
2. Self-report of any change in medication treating bipolar disorder and any psychiatric condition, including a change in dosage, in the previous 6 months and as screened by CORE Therapy Assessment Form v.2.
3. Current suicidal intent as screened by CORE-OM and CORE Therapy Assessment Form v.2.
4. Currently participating in couple or family therapy.
5. Diagnosis of intellectual or developmental disability as screened by CORE Therapy Assessment Form v.2.
6. Significant brain injury or medical condition leading to cognitive impairment (e.g. accident, tumor) as screened by CORE Therapy Assessment Form v.2.
7. Self-report of any change in medication treating MS, including a change dosage, in the previous 3 months.
8. Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
Clareo Health | Resilience-Based Program for Support Partners of Persons With Multiple Sclerosis
